Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.

Revenue
+34.1%
EPS
+34.4%
Free cash flow
−85.8%
Total debt
−0.06%

Quarter to September 2026, against a year earlier

365.77 25.26 −6.46%
Market cap
$52.4B
P/E
0.0×
Fwd P/E
−289×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a

Natera, Inc. (NTRA) Debt to equity

Alert me on Debt to equity

Natera, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 4.8× (fiscal 2017) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.0× (30.21%)
FY2024 0.1× (85.85%)
FY2023 0.5× (7.43%)
FY2022 0.5× 1.40%
FY2021 0.5× (2.62%)
FY2020 0.5× 16.96%
FY2019 0.4× (88.44%)
FY2018 3.8× (20.76%)
FY2017 4.8× 939.73%
FY2016 0.5× 104.61%

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× (2.72%)
Jun 2026 0.0× (2.65%)
Mar 2026 0.0× (3.41%)
Dec 2025 0.0× (26.95%)
43 more quarters

Against its own ten years

Low 0.0× High 4.8×
Ten-year median 0.5×
Current reading's percentile 9

Debt to equity against peers

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on NTRA